Posted by Michael Wonder on 01 Mar 2025
Valneva receives EMA’s positive CHMP opinion for adolescent label extension for chikungunya vaccine Ixchiq
28 February 2025 - If granted, Ixchiq will become the first vaccine against the chikungunya virus available in the EU for adolescents 12 years of age and older.
Valneva today announced that the CHMP of the EMA has adopted a positive opinion recommending authorisation of a label extension for Ixchiq, Valneva’s single dose vaccine for the prevention of disease caused by the chikungunya virus, to individuals 12 years of age and older.
